582 related articles for article (PubMed ID: 34246549)
1. The pathologic relevance of metabolic criteria in patients with biopsy-proven nonalcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: A multicenter cross-sectional study in China.
Yang RX; Zou ZS; Zhong BH; Deng H; He FP; Shi JP; Zhao CY; Mi YQ; Zhou YJ; Di FS; Zheng RD; Du Q; Shang J; Popovic B; Chen J; Fan JG
Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):426-432. PubMed ID: 34246549
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
[TBL] [Abstract][Full Text] [Related]
3. Association of
Toda-Oti KS; Stefano JT; Cavaleiro AM; Carrilho FJ; Correa-Gianella ML; Oliveira CPMS
Metab Syndr Relat Disord; 2022 Mar; 20(2):114-123. PubMed ID: 35020496
[No Abstract] [Full Text] [Related]
4. IS HOMEOSTASIS MODEL ASSESSMENT FOR INSULIN RESISTANCE >2.5 A DISTINGUISHED CRITERIA FOR METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE IDENTIFICATION?
Barreto BFM; Punaro GR; Elias MC; Parise ER
Arq Gastroenterol; 2022; 59(3):402-407. PubMed ID: 36102439
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
6. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects.
Ampuero J; Aller R; Gallego-Durán R; Crespo J; Abad J; González-Rodríguez Á; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Martín-Mateos R; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Hernández-Guerra M; Augustín S; Pareja-Megia MJ; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero-Gómez M;
Liver Int; 2021 Sep; 41(9):2076-2086. PubMed ID: 33896100
[TBL] [Abstract][Full Text] [Related]
7. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.
Pelusi S; Cespiati A; Rametta R; Pennisi G; Mannisto V; Rosso C; Baselli G; Dongiovanni P; Fracanzani AL; Badiali S; Maggioni M; Craxi A; Fargion S; Prati D; Nobili V; Bugianesi E; Romeo S; Pihlajamaki J; Petta S; Valenti L
Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111
[TBL] [Abstract][Full Text] [Related]
9. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
10. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
11. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
van Kleef LA; Ayada I; Alferink LJM; Pan Q; de Knegt RJ
Hepatology; 2022 Feb; 75(2):419-429. PubMed ID: 34453359
[TBL] [Abstract][Full Text] [Related]
12. A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China: a cross-sectional study.
Liu Q; Zhao G; Li Q; Wu W; Zhang Y; Bian H
BMC Gastroenterol; 2022 Nov; 22(1):471. PubMed ID: 36402947
[TBL] [Abstract][Full Text] [Related]
13. Association between the CYBA and NOX4 genes of NADPH oxidase and its relationship with metabolic syndrome in non-alcoholic fatty liver disease in Brazilian population.
Rabelo F; Stefano JT; Cavaleiro AM; Lima RVC; de Campos Mazo DF; Carrilho FJ; Correa-Giannella ML; Oliveira CP
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):330-335. PubMed ID: 30087027
[TBL] [Abstract][Full Text] [Related]
14. Irisin in patients with nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
[TBL] [Abstract][Full Text] [Related]
15. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
[TBL] [Abstract][Full Text] [Related]
16. Severity of metabolic syndrome is greater among nonalcoholic adults with elevated ALT and advanced fibrosis.
DeBoer MD; Lin B; Filipp SL; Cusi K; Gurka MJ
Nutr Res; 2021 Apr; 88():34-43. PubMed ID: 33743323
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome.
Sinn DH; Kang D; Choi SC; Hong YS; Zhao D; Guallar E; Park Y; Cho J; Gwak GY
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1873-1880.e1. PubMed ID: 36152895
[TBL] [Abstract][Full Text] [Related]
18. Potential screening indicators for early diagnosis of NAFLD/MAFLD and liver fibrosis: Triglyceride glucose index-related parameters.
Xue Y; Xu J; Li M; Gao Y
Front Endocrinol (Lausanne); 2022; 13():951689. PubMed ID: 36120429
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease.
Duseja A; Singh SP; Mehta M; Shalimar ; Venkataraman J; Mehta V; Devadas K; Kar SK; Goyal O; Nagral A; Saigal S; Nijhawan S; Praharaj D; Shukla A; Sharma B; Narayanasamy K; Kumar P; Rao PN; Arora A; Mehta R; Asati P; Ranjan P; Koshy A; Alam S; Mukewar S; Mukewar S; Mohan Prasad VG; Rastogi M; Sanyal AJ
Metab Syndr Relat Disord; 2022 Apr; 20(3):166-173. PubMed ID: 35085026
[No Abstract] [Full Text] [Related]
20. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]